MedTrace Logo

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

NCT03655483 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2020-06-11

No results posted yet for this study

Summary

Patients with refractory cHL. Patients will be treated with GLS-010

Conditions

  • Classical Hodgkin's Lymphoma

Interventions

DRUG

GLS-010

Full-human anti-pd-1 monoclonal antibodies

Sponsors & Collaborators

  • Guangzhou Gloria Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jun Zhu, MD · Peking University Cancer Hospital & Institute

  • Yuqin Song, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-24
Primary Completion
2021-04-11
Completion
2022-04-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03655483 on ClinicalTrials.gov